CN1154483C - 胺化合物用于制备阻止肿瘤细胞增殖的药物 - Google Patents
胺化合物用于制备阻止肿瘤细胞增殖的药物 Download PDFInfo
- Publication number
- CN1154483C CN1154483C CNB971968853A CN97196885A CN1154483C CN 1154483 C CN1154483 C CN 1154483C CN B971968853 A CNB971968853 A CN B971968853A CN 97196885 A CN97196885 A CN 97196885A CN 1154483 C CN1154483 C CN 1154483C
- Authority
- CN
- China
- Prior art keywords
- cyclohexyl
- phenyl
- chloro
- amine
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Indole Compounds (AREA)
Abstract
Description
ST 31747 | U266 | RPMI 8226 | MCF-7 | 293 | A549 |
10μM | 11 | 6 | 5 | 7 | 10 |
1μM | 52 | 9 | 34 | 10 | 14 |
100nM | 67 | 54 | 58 | 36 | 38 |
10nM | 82 | 66 | 75 | 43 | 50 |
1nM | 95 | 79 | 83 | 80 | 56 |
100pM | 100 | 91 | 100 | 84 | 88 |
10pM | 100 | 100 | 100 | 100 | 100 |
细胞 | 敏感性 | 10%FCS | 0.5%FCS | 0.1%FCS | 0%FCS |
MCF7 p23-25 | 激素敏感的 | 2×5 10-7M10-7M | 2×10-9M2×10-8M | ||
MCF7 PRMI p6-7 | 激素敏感的 | 7×10-8M | 3×10-8M | ||
MCF7 22HTBRPMI p+4 | 激素敏感的 | 2×10-9M | |||
LY2 p22-23 | 抗***抗性的 | >10-7M>10-7M | 10-12M5×10-12M | ||
MCF7 AZTD5 | H-ras转染的抗*** | 6×10-7M | 2×10-10M | ||
SN 47 p4 | 正常细胞 | >10-6M | 4×10-7M | ||
MCF7 AZ | 激素敏感的 | >10-6M | 2×5 10-8M | ||
MCF7+E2 10-9M | 激素敏感的 | 4×10-7M4×10-7M4×10-7M | 5×10-10M2×10-9M2×10-9M | ||
MDA MB231p131 | 激素敏感的 | 8×10-7M4×10-7M | 2×10-9M2×10-9M | ||
LCC1 p23-24 | 不依赖***的 | 5%FCS10-6M | 2×10-9M | ||
LCC2 p26-27 | 不依赖***的抗***抗性 | 5%DCC4×10-7M3×10-7M | 0.1%DCC2×10-9M2×10-9M |
Claims (3)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR96/09531 | 1996-07-29 | ||
FR9609531A FR2751645B1 (fr) | 1996-07-29 | 1996-07-29 | Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1226825A CN1226825A (zh) | 1999-08-25 |
CN1154483C true CN1154483C (zh) | 2004-06-23 |
Family
ID=9494593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB971968853A Expired - Fee Related CN1154483C (zh) | 1996-07-29 | 1997-07-28 | 胺化合物用于制备阻止肿瘤细胞增殖的药物 |
Country Status (31)
Country | Link |
---|---|
US (1) | US6235791B1 (zh) |
EP (1) | EP0917464B1 (zh) |
JP (1) | JP3538431B2 (zh) |
KR (1) | KR100315559B1 (zh) |
CN (1) | CN1154483C (zh) |
AR (1) | AR008090A1 (zh) |
AT (1) | ATE266392T1 (zh) |
AU (1) | AU735948B2 (zh) |
BR (1) | BR9711606A (zh) |
CA (1) | CA2261827C (zh) |
CZ (1) | CZ294266B6 (zh) |
DE (1) | DE69729099T2 (zh) |
DK (1) | DK0917464T3 (zh) |
EE (1) | EE03851B1 (zh) |
ES (1) | ES2221061T3 (zh) |
FR (1) | FR2751645B1 (zh) |
HU (1) | HU224346B1 (zh) |
ID (1) | ID17707A (zh) |
IL (1) | IL127922A (zh) |
IS (1) | IS2049B (zh) |
MY (1) | MY120426A (zh) |
NO (1) | NO322897B1 (zh) |
NZ (1) | NZ333957A (zh) |
PT (1) | PT917464E (zh) |
RU (1) | RU2176502C2 (zh) |
SI (1) | SI0917464T1 (zh) |
SK (1) | SK285344B6 (zh) |
TR (1) | TR199900161T2 (zh) |
UA (1) | UA61080C2 (zh) |
WO (1) | WO1998004251A1 (zh) |
ZA (1) | ZA976697B (zh) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2143403B1 (es) * | 1998-03-13 | 2001-01-01 | Consejo Superior Investigacion | Derivados de ciclopropenilaminas como agentes anticancerosos. |
GB9814036D0 (en) | 1998-06-29 | 1998-08-26 | Univ Dundee | Materials and methods relating to the induction of apoptosis in target cells |
FR2794742B1 (fr) * | 1999-06-11 | 2005-06-03 | Sanofi Synthelabo | Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant |
FR2795724B1 (fr) * | 1999-07-02 | 2002-12-13 | Sanofi Synthelabo | Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant |
FR2803593B1 (fr) * | 2000-01-06 | 2002-02-15 | Sanofi Synthelabo | Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant |
ES2266618T3 (es) * | 2001-08-23 | 2007-03-01 | Bayer Cropscience S.A. | Propargilaminas substituidas. |
FR2887454B1 (fr) * | 2005-06-28 | 2009-06-05 | Sanofi Aventis Sa | Combinaisons antitumorales contenant des derives du taxane et des sigma ligands |
US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
KR20090024811A (ko) | 2006-06-23 | 2009-03-09 | 아보트 러보러터리즈 | 히스타민 h3 수용체 조절제로서의 사이클로프로필 아민 유도체 |
JP2010523476A (ja) | 2007-03-08 | 2010-07-15 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | ミトコンドリアアルデヒドデヒドロゲナーゼ−2モジュレーター及びその使用方法 |
JP2012502048A (ja) | 2008-09-08 | 2012-01-26 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法 |
JP2012506856A (ja) | 2008-10-28 | 2012-03-22 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法 |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
US10457659B2 (en) | 2011-04-29 | 2019-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
US20150175534A1 (en) * | 2012-08-01 | 2015-06-25 | Merck Sharp & Dohme Corp. | Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I |
CN105358531B (zh) | 2013-03-14 | 2017-11-14 | 利兰-斯坦福大学初级学院的董事会 | 线粒体醛脱氢酶‑2调节剂和其使用方法 |
SG11201808220VA (en) | 2016-03-22 | 2018-10-30 | Merck Sharp & Dohme | Allosteric modulators of nicotinic acetylcholine receptors |
IL300858A (en) | 2020-09-17 | 2023-04-01 | Meletios Therapeutics | Compounds for the treatment of viral infection |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3674832A (en) * | 1968-08-22 | 1972-07-04 | Schering Corp | Cyclopropane carboxylic acid derivatives |
FR2132547A1 (en) * | 1971-04-08 | 1972-11-24 | Clin Byla Ets | Substd phenyl alkyl or alkenyl amides - useful as analgesics and antiinflammatories |
GB1475314A (en) * | 1973-11-02 | 1977-06-01 | Cm Ind | Phenyl-propylamine derivatives |
US4104383A (en) | 1973-11-02 | 1978-08-01 | C M Industries | Derivatives of phenylpropenylamine |
IT1113391B (it) * | 1979-05-09 | 1986-01-20 | Maggioni Farma | Derivati fenilcicloesanici ad attivita' antidepressiva |
US4537902A (en) * | 1979-06-11 | 1985-08-27 | Merck & Co., Inc. | 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase |
FR2641276B1 (fr) | 1988-12-30 | 1991-07-12 | Sanofi Sa | Derives du benzene, leur preparation et les compositions pharmaceutiques en contenant |
JP2814694B2 (ja) | 1989-07-21 | 1998-10-27 | セイコーエプソン株式会社 | 識別コード読み書き構造及びその装置及びその方法 |
FR2663328B1 (fr) * | 1990-06-14 | 1994-08-05 | Sanofi Sa | Derives d'hexahydroazepines, un procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2694287B1 (fr) * | 1992-07-31 | 1994-09-16 | Jouveinal Inst Rech | Nouvelles cycloalkylalkylamines ligands aux récepteurs sigma, leur procédé de préparation et leur application en thérapeutique. |
FR2713639B1 (fr) * | 1993-12-09 | 1996-08-30 | Irj | Nouveaux dérivés de 2-arylalkényl-azacycloalkanes ligands aux récepteurs sigma, leur procédé de préparation et leur application en thérapeutique. |
FR2724656B1 (fr) * | 1994-09-15 | 1996-12-13 | Adir | Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2725445B1 (fr) * | 1994-10-10 | 1996-10-31 | Adir | Nouveaux derives a structure 1-arylalkenyl 4-aryl alkyl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US5919934A (en) * | 1997-02-19 | 1999-07-06 | The George Washington University | Compounds, compositions, and methods for cancer imaging and therapy |
-
1996
- 1996-07-29 FR FR9609531A patent/FR2751645B1/fr not_active Expired - Fee Related
-
1997
- 1997-07-28 DK DK97935643T patent/DK0917464T3/da active
- 1997-07-28 WO PCT/FR1997/001409 patent/WO1998004251A1/fr active IP Right Grant
- 1997-07-28 KR KR1019997000698A patent/KR100315559B1/ko not_active IP Right Cessation
- 1997-07-28 EE EEP199900029A patent/EE03851B1/xx not_active IP Right Cessation
- 1997-07-28 CN CNB971968853A patent/CN1154483C/zh not_active Expired - Fee Related
- 1997-07-28 AR ARP970103405A patent/AR008090A1/es unknown
- 1997-07-28 CA CA002261827A patent/CA2261827C/fr not_active Expired - Fee Related
- 1997-07-28 CZ CZ1999242A patent/CZ294266B6/cs not_active IP Right Cessation
- 1997-07-28 RU RU99104150/14A patent/RU2176502C2/ru not_active IP Right Cessation
- 1997-07-28 AT AT97935643T patent/ATE266392T1/de not_active IP Right Cessation
- 1997-07-28 PT PT97935643T patent/PT917464E/pt unknown
- 1997-07-28 UA UA99021083A patent/UA61080C2/uk unknown
- 1997-07-28 SK SK79-99A patent/SK285344B6/sk not_active IP Right Cessation
- 1997-07-28 JP JP50856798A patent/JP3538431B2/ja not_active Expired - Fee Related
- 1997-07-28 BR BR9711606A patent/BR9711606A/pt not_active Application Discontinuation
- 1997-07-28 ES ES97935643T patent/ES2221061T3/es not_active Expired - Lifetime
- 1997-07-28 US US09/230,643 patent/US6235791B1/en not_active Expired - Fee Related
- 1997-07-28 HU HU9902806A patent/HU224346B1/hu not_active IP Right Cessation
- 1997-07-28 ID IDP972614A patent/ID17707A/id unknown
- 1997-07-28 TR TR1999/00161T patent/TR199900161T2/xx unknown
- 1997-07-28 ZA ZA9706697A patent/ZA976697B/xx unknown
- 1997-07-28 NZ NZ333957A patent/NZ333957A/xx unknown
- 1997-07-28 SI SI9730649T patent/SI0917464T1/xx unknown
- 1997-07-28 EP EP97935643A patent/EP0917464B1/fr not_active Expired - Lifetime
- 1997-07-28 DE DE69729099T patent/DE69729099T2/de not_active Expired - Fee Related
- 1997-07-28 AU AU38551/97A patent/AU735948B2/en not_active Ceased
- 1997-07-28 IL IL12792297A patent/IL127922A/xx not_active IP Right Cessation
- 1997-07-29 MY MYPI97003451A patent/MY120426A/en unknown
-
1999
- 1999-01-19 IS IS4946A patent/IS2049B/is unknown
- 1999-01-28 NO NO19990401A patent/NO322897B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1154483C (zh) | 胺化合物用于制备阻止肿瘤细胞增殖的药物 | |
CN1153764C (zh) | 取代的苄氨基哌啶化合物 | |
CN1028105C (zh) | 四氢吡啶衍生物的制备方法 | |
CN1158258C (zh) | 肾上腺素能α1B受体拮抗药 | |
CN101050194A (zh) | 双环辛烷类衍生物、其制备方法及其在医药上的用途 | |
CN1020093C (zh) | 1-苯基-3-萘氧基丙胺的制备方法 | |
CN1210250C (zh) | 苯衍生物、其制备方法以及含有它们的药用组合物 | |
CN1699343A (zh) | 盐酸多奈哌齐的多晶型物及其制备方法 | |
CN1195519C (zh) | 5-HT再摄取抑制剂与h5-HT1B拮抗剂或部分激动剂的组合物 | |
CN1067655A (zh) | 含氮杂环类化合物的氟代烷氧基苄氨基衍生物 | |
CN1173964C (zh) | 新型苯并呋喃酮衍生物及其制备方法 | |
CN1150165C (zh) | 用于治疗中枢神经***紊乱的1-芳基磺酰基-2-芳基-吡咯烷衍生物 | |
CN1072219C (zh) | 二氮杂䓬酮、其生产和用途 | |
CN1229373C (zh) | 作为神经激肽1拮抗剂的哌啶衍生物 | |
CN1053658C (zh) | 氨基芪唑衍生物和药 | |
CN1655785A (zh) | 治疗摄食障碍中用作黑皮素受体配体的n-酰基哌啶衍生物 | |
CN1571782A (zh) | 作为3型17β-羟基类固醇脱氢酶抑制剂用于治疗雄激素依赖疾病的哌啶乙酰胺类化合物和哌嗪乙酰胺类化合物 | |
CN86106294A (zh) | 二氢吡啶类的制备方法 | |
CN1721417A (zh) | 新的吡咯烷和噻唑烷化合物、它们的制备方法和包含它们的药物组合物 | |
CN1022103C (zh) | 制备取代苯乙烯衍生物及其药用酸加成盐和其季铵盐的方法 | |
CN1124026A (zh) | 新型哌啶基硫代吲哚衍生物,它们的制备方法,和含有它们的药物组合物,作为止痛药的用途 | |
CN1068819A (zh) | 新的选择性芳族酶抑制4(5)-咪唑 | |
CN1156462C (zh) | 抗精神病的环状n-芳烷基胺 | |
CN1620452A (zh) | 3,4-二氢-1h-异喹啉-2-基-衍生物 | |
CN1257864A (zh) | 新的咪唑啉化合物、其制备方法和含有它们的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Applicant after: SANOFI-SYNTHELABO Co., Ltd. Applicant before: Sanofi |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SANOFI CORP. TO: SANOFI-SANOFI-SYNTHELABO SA |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: SANOFI. AVENTIS CO., LTD. Free format text: FORMER NAME OR ADDRESS: SANOFI-SANOFI-SYNTHELABO SA |
|
CP01 | Change in the name or title of a patent holder |
Address after: France Patentee after: Sanofi Aventis Address before: France Patentee before: SANOFI-SYNTHELABO Co., Ltd. |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040623 |